EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024

Description:

EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024

Summary

Ankylosing spondylitis (AS) - a systemic, chronic, and progressive inflammatory arthritis, is the prototype of a family of related disorders known as seronegative spondyloarthritis (SpA) and one of the most common rheumatic diseases across the globe. AS primarily affects the spine and sacroiliac (SI) joints and progresses into severe inflammation that fuses the spine, leading to permanent painful stiffness of the back. AS that occurs before any structural changes in the spine is referred to as non-radiographic axial spondyloarthritis (nr-axSpA) which is the early stage of AS. Some of non-radiographic axial spondyloarthritis progress to AS and some do not.

Our epidemiological analysis provides a country-specific forecast for the diagnosed prevalent cases of AS in the 7MM during 2014-2024. The publisher epidemiologists made sure all the country-specific studies report diagnosed prevalent cases of AS, diagnosed prevalent cases of nr-axSpA, and HLA-B27 seropositivity cases in diagnosed AS cases based on medical chart review by a physician or data extracted from national registries. The publisher epidemiologists provide a forecast for the diagnosed prevalent cases of AS and nr-axSpA using two different approaches: 1) forecasting the diagnosed prevalent cases of AS and nr-axSpA using data obtained from peer reviewed journal articles and 2) forecasting the diagnosed prevalent cases of AS and nr-axSpA by applying a trend based on data obtained from primary research to the diagnosed prevalent cases calculated using the base scenario. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

The diagnosed prevalent cases of AS in the 7MM in the base scenario increased from 1,045,903 diagnosed prevalent cases in 2014 to 1,067,905 diagnosed prevalent cases in 2024, with an annual growth rate (AGR) of 0.21%. The forecast in the alternate scenario based on primary research data showed that there will be a substantial increase in the diagnosed prevalent cases of AS in the 7MM from 1,279,010 diagnosed prevalent cases in 2014 to 2,230,825 diagnosed prevalent cases in 2024, at an AGR of 7.44%. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

Scope

- The Ankylosing Spondylitis EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for ankylosing spondylitis (AS) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of ankylosing spondylitis segmented by sex, age (in ten-year increments beginning at 15 years and ending at =65 years), and diagnosed prevalent cases of non-radiographic axial spondyloarthritis, and diagnosed prevalent cases of AS segmented by HLA-B27 seropositivity status in these markets.
- The ankylosing spondylitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Ankylosing Spondylitis EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global ankylosing spondylitis market.
- Quantify patient populations in the global ankylosing spondylitis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ankylosing spondylitis therapeutics in each of the markets covered.

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global Trends
3.3.1 US
3.3.2 EU
3.3.3 Japan
3.4 Forecast Methodology
3.4.1 Sources Used for Diagnosed Prevalence of AS
3.4.2 Sources used for Diagnosed Prevalence of Nr-axSpA
3.4.3 Sources Used for the Prevalence of HLA-B27 Seropositivity in Diagnosed AS
3.4.4 Sources Not Used
3.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario
3.4.6 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA - Base Scenario
3.4.7 Forecast Assumptions and Methods, HLA-B27 Seropositivity in Diagnosed AS
3.4.8 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSp - Alternative Scenario
3.4.9 Forecast Assumptions and Methods, HLA-B27 Seropositivity in Diagnosed AS Cases
3.5 Epidemiological Forecast for AS (2014-2024) - Base Scenario
3.5.1 Diagnosed Prevalent Cases of AS
3.5.2 Age-Specific Diagnosed Prevalent Cases of AS
3.5.3 Sex-Specific Diagnosed Prevalent Cases of AS
3.5.4 Age-Standardized Diagnosed Prevalence of AS
3.5.5 Diagnosed Prevalent Cases of Nr-axSpA
3.5.6 Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases
3.6 Epidemiological Forecast for AS (2014-2024) - Alternative Scenario
3.6.1 Diagnosed Prevalent Cases of AS
3.6.2 Diagnosed Prevalent Cases of Nr-axSpA
3.7 Discussion
3.7.1 Epidemiological Forecast Insight
3.7.2 Limitations of the Analysis
3.7.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologists
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head of Healthcare
4.3 About Us
4.4 About EpiCast
4.5 Disclaimer

1.1 List of Tables
Table 1: Diagnostic Criterion for AS and Nr-axSpA
Table 2: Risk Factors and Comorbidities for AS
Table 3: Summary of the Global Reported Prevalence of AS
Table 4: Incidence of AS, Cases per 100,000 Population, 1935-1973, Rochester, Minnesota, US
Table 5: Annual Incidence of AS, Cases per 100,000 Population, 1980-1990, Finland
Table 6: 7MM, Sources of Diagnosed Prevalence Data for AS used in the Epidemiology Forecast
Table 7: 7MM, Sources of Diagnosed Prevalence Data for Nr-axSpA used in the Epidemiology Forecast
Table 8: 7MM, Sources of HLA-B27 Seropositivity Data in Diagnosed AS Cases used in the Epidemiology Forecast
Table 9: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages =15 Years, Select Years, N, 2014-2024
Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N (Row %), 2014
Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages =15 Years, N (Row %), 2014
Table 12: 7MM, Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, Ages =15 Years, Select Years, N, 2014-2024
Table 13: 6MM, Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases, Both Sexes, Ages =15 Years, Select Years, N, 2014-2024
Table 14: 6MM, HLA-B27 and Non-HLA-B27 Seropositivity Status Among Diagnosed AS Cases, Both Sexes, Ages =15 Years, N, 2014
Table 15: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages =15 Years, Select Years, N, 2014-2024
Table 16: 7MM, Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, Ages =15 Years, Select Years, N, 2014-2024

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages =15 Years, N, 2014-2024
Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N, 2014
Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages =15 Years, N, 2014
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of AS, Cases per 100,000 Population, Men and Women, 2014
Figure 5: 7MM, Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, Ages =15 Years, N, 2014-2024
Figure 6: 6MM, Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases, Both Sexes, Ages =15 Years, N, 2014-2024
Figure 7: 6MM, HLA-B27 and Non-HLA-B27 Seropositivity Status Among Diagnosed AS Cases, Both Sexes, Ages =15 Years, N, 2014
Figure 8: 7MM, Diagnosed Prevalent Cases of AS, Both Sexes, Ages =15 Years, N, 2014-2024
Figure 9: 7MM, Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, Ages =15 Years, N, 2014-2024

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3385409/](http://www.researchandmarkets.com/reports/3385409/)
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024
Web Address: http://www.researchandmarkets.com/reports/3385409/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Electronic (PDF) - Single User:</th>
<th>USD 3995</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 11985</td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) - Site License:</td>
<td>USD 7990</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World